Michael  Mason net worth and biography

Michael Mason Biography and Net Worth

Mike joined Karyopharm in February 2019 and is responsible for leading and directing the financial activities of the Company.  He has over 18 years of diversified financial experience in executing financial strategies and leading growth initiatives for life sciences companies. He has deep expertise in global financial operations and controls, financing transactions, business planning and supporting pharmaceutical product launches.

Prior to joining Karyopharm, Mike spent over 13 years at Alnylam Pharmaceuticals, Inc. in a progression of finance roles. Most recently, he served as Vice President of Finance and Treasurer at Alnylam. Earlier in his career, Mike served as the Corporate Controller at Praecis Pharmaceuticals and previously worked in the audit practice at KPMG LLP, a national audit, tax and advisory services firm.

Mike received a Bachelor of Business Administration from Stetson University and an MBA from Babson College.  He is also a Certified Public Accountant.

What is Michael Mason's net worth?

The estimated net worth of Michael Mason is at least $611,426.18 as of February 29th, 2024. Mr. Mason owns 404,918 shares of Karyopharm Therapeutics stock worth more than $611,426 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Mason may own. Additionally, Mr. Mason receives an annual salary of $681,590.00 as CFO at Karyopharm Therapeutics. Learn More about Michael Mason's net worth.

How old is Michael Mason?

Mr. Mason is currently 49 years old. There are 6 older executives and no younger executives at Karyopharm Therapeutics. The oldest executive at Karyopharm Therapeutics is Mr. Cameron Peters, Vice President of Finance, Assistant Treasurer & Principal Accounting Officer, who is 64 years old. Learn More on Michael Mason's age.

What is Michael Mason's salary?

As the CFO of Karyopharm Therapeutics Inc., Mr. Mason earns $681,590.00 per year. There are 2 executives that earn more than Mr. Mason. The highest earning executive at Karyopharm Therapeutics is Dr. Sharon Shacham M.B.A., Ph.D., Co-Founder & Chairman of Scientific Advisory Board, who commands a salary of $1,400,000.00 per year. Learn More on Michael Mason's salary.

How do I contact Michael Mason?

The corporate mailing address for Mr. Mason and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Michael Mason's contact information.

Has Michael Mason been buying or selling shares of Karyopharm Therapeutics?

Over the course of the past ninety days, Michael Mason has sold $42,439.14 in Karyopharm Therapeutics stock. Most recently, Michael Mason sold 27,687 shares of the business's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $1.17, for a transaction totalling $32,393.79. Following the completion of the sale, the chief financial officer now directly owns 404,918 shares of the company's stock, valued at $473,754.06. Learn More on Michael Mason's trading history.

Who are Karyopharm Therapeutics' active insiders?

Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Michael Kauffman (Director), Michael Mason (CFO), Stephen Mitchener (SVP), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.

Are insiders buying or selling shares of Karyopharm Therapeutics?

During the last twelve months, Karyopharm Therapeutics insiders bought shares 1 times. They purchased a total of 41,140 shares worth more than $50,190.80. During the last twelve months, insiders at the sold shares 23 times. They sold a total of 220,142 shares worth more than $307,609.71. The most recent insider tranaction occured on March, 5th when CEO Richard A Paulson sold 3,573 shares worth more than $4,644.90. Insiders at Karyopharm Therapeutics own 3.3% of the company. Learn More about insider trades at Karyopharm Therapeutics.

Information on this page was last updated on 3/5/2024.

Michael Mason Insider Trading History at Karyopharm Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/29/2024Sell27,687$1.17$32,393.79404,918View SEC Filing Icon  
2/27/2024Sell2,545$1.32$3,359.40244,400View SEC Filing Icon  
2/6/2024Sell4,205$1.59$6,685.95246,945View SEC Filing Icon  
9/1/2023Sell6,913$1.33$9,194.29237,817View SEC Filing Icon  
3/1/2023Sell11,205$3.03$33,951.15245,361View SEC Filing Icon  
6/3/2022Sell601$6.04$3,630.04138,509View SEC Filing Icon  
2/7/2022Sell3,947$9.86$38,917.42View SEC Filing Icon  
See Full Table

Michael Mason Buying and Selling Activity at Karyopharm Therapeutics

This chart shows Michael Mason's buying and selling at Karyopharm Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics logo
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Read More

Today's Range

Now: $1.51
Low: $1.43
High: $1.60

50 Day Range

MA: $1.26
Low: $0.75
High: $1.66

2 Week Range

Now: $1.51
Low: $0.62
High: $4.87

Volume

1,266,327 shs

Average Volume

1,775,451 shs

Market Capitalization

$173.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.01